Business Context and Reporting Period
This Form 8-K filing by BioSig Technologies, Inc. (BSGM) reports a material definitive agreement entered into on February 28, 2025. The company, incorporated in Delaware, is based in Los Angeles, California. The filing details a new equity financing arrangement rather than a standard periodic financial report.
Key Financial Metrics and Agreement Terms
- Commitment Amount: Up to $5.0 million in common stock available for purchase by the investor over 36 months.
- Share Cap: Limited to 10,000,000 shares total under the agreement.
- Exchange Cap: Issuance is capped at 4,605,765 shares (19.99% of outstanding shares) unless shareholder approval is obtained or specific price thresholds are met.
- Pricing Mechanism: Shares are sold at 95% of the lowest daily VWAP during a five-day period following an advance notice.
- Commitment Shares: 108,542 shares issued immediately to the investor as consideration for the commitment.
- Ownership Limit: Investor beneficial ownership is restricted to 4.99% (adjustable up to 9.99% with notice).
Material Changes and Conditions
The primary material change is the establishment of an Equity Subscription Agreement with Lind Global Fund III, LP. Key conditions include:
- Voluntary Execution: The company has the right, but not the obligation, to sell shares. There is no assurance that any shares will be sold or proceeds received.
- Registration Requirement: The investor's obligation to purchase is contingent upon the company filing a registration statement (Form S-1 or S-3) and having it declared effective by the SEC.
- Expense Advance: The company previously advanced $10,000 to the investor to cover expenses related to the agreement.
Outlook, Risks, and Contingencies
Management retains full control over the timing and amount of any future sales, which will depend on market conditions and funding needs. The filing explicitly states that there can be no assurance that the company will sell any shares or receive proceeds. The agreement is subject to Nasdaq rules regarding the 19.99% exchange cap, which may require shareholder approval for issuances exceeding this limit unless the average sale price meets or exceeds $0.88 per share.
Investor Verification Checklist
- Verify the status of the required Form S-1 or S-3 registration statement to confirm the investor's obligation to purchase is active.
- Monitor the current trading price relative to the $0.88 threshold to assess the likelihood of needing shareholder approval for future issuances.
- Review the 108,542 commitment shares issued to determine immediate dilution impact.
- Confirm whether the company intends to utilize the $5.0 million commitment given the voluntary nature of the sales.